Hansizhuang (serplulimab), the world's first anti-PD-1 monoclonal antibody (mAb) treatment for extensive-stage small cell lung cancer (ES-SCLC), enhanced survival rates compared to chemotherapy, and is projected to be the leading immunotherapy for the disease in the next five years.
List view / Grid view
Extensive-stage small cell lung cancer (ES-SCLC)
Roughly 17.6 percent of patients treated with Imfinzi plus chemotherapy were alive at three years, versus 5.8 percent of chemotherapy patients.
Imfinzi (durvalumab) has been approved by the European Commission as a first-line treatment for extensive-stage small cell lung cancer, with chemotherapy.